TLP
BCRX icon

Tri Locum Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Tri Locum Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-17,260
Closed -$129K – 41
2020
Q4 		$129K Buy
+17,260
New +$89K 0.05% 63

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Tri Locum Partners's BCRX Position: Q1 2021 in Review

Tri Locum Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2021, closing a stake of 17,260 shares — an estimated $129K sold.

Tri Locum Partners first reported a position in BCRX in Q4 2020 and held it in 1 quarter. The position peaked at $129K in Q4 2020. 191 funds tracked by Wall St. Rank hold BCRX as of Q1 2021.

  • Tri Locum Partners reported no remaining BioCryst Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Tri Locum Partners sold 17,260 BioCryst Pharmaceuticals shares in Q1 2021, an estimated $129K.
  • Tri Locum Partners first reported a position in BioCryst Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Tri Locum Partners's BioCryst Pharmaceuticals position peaked at $129K in Q4 2020.
  • 191 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2021.

Based on Tri Locum Partners's 13F filing for Q1 2021, filed 17 May 2021.